This is a feasibility study to collect tumor and peripheral blood of patients with advanced NSCLC who receive treatment. Blood will also be collected from subjects without lung cancer to assess non cancer profiles. To conduct this study, a total of 30 study-eligible subjects of all races and ethnicities, aged 18 years or older with a diagnosis of Stage IV adenocarcinoma of the lung (Cohort A), will be enrolled and have their tumor collected once for molecular profiling and xenograft development and blood collected at prespecified time intervals until completion of treatment for liquid biopsy analysis (targeted sequencing, whole exome sequencing, whole genome sequencing). A total of 60 study-eligible subjects of all races and ethnicities ages 18 years or older will be enrolled in the non-lung cancer control subgroups chronic inflammatroy disorder (Cohort B), smokers at risk to develop lung cancer (Cohort C).